H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Bioxcel Therapeutics Inc (NASDAQ: BTAI) today and set a price target of $25. The company’s shares closed on Friday at $10.94.
According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 1.2% and a 44.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Bioxcel Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $23, which is an 110.2% upside from current levels. In a report issued on July 3, Canaccord Genuity also maintained a Buy rating on the stock with a $21 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $14.79 and a one-year low of $6.76. Currently, Bioxcel Therapeutics Inc has an average volume of 47.34K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focuses on drug development. The firm’s two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in Branford, CT.
